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Abstract
Bone grafts are used in 2 million annual surgeries with that statistic expected to rise
due to the increasing elderly population as well as sports related injuries. At a certain size
bone fracture or defect, the body is unable to heal spontaneously, and a bone graft must
be implanted into the defect site. Allografts are used as bone grafts due to their
availability and elimination of donor site morbidity, however they show poor bioactivity
and bone regeneration. This study utilizes a degradable poly(lactic-co-glycolide) (PLGA)
polymer coating applied to cancellous allografts, loaded with a variety of therapeutic
agents aimed to improve the bioactivity of the allografts. Bone morphogenetic protein-2
(BMP-2) was physically encapsulated in the polymer coating, the antibiotic
gentamicin was physically encapsulated and surface adsorbed, and previous studies
surface adsorbed the growth factor vascular endothelial growth factor (VEGF). Results
show that encapsulated proteins followed the trend of a moderate burst release within the
first day of release, followed by sustained release for the 6 week time period that
followed. Surface adsorbed tests additionally show a larger burst release in the first day,
followed by a less gradual, faster release of 100% of protein. Qualitative results of an in
vivo study using cortical allografts with dual coating of encapsulated BMP-2 and surface
adsorbed VEGF showed enhanced bone callus formation in the combined group
compared to BMP-2 alone, with X-Ray and MicroCT imaging showing a near bony
union by 8 weeks in the combined group.

viii

1.0. Introduction
1.1. Physiology of Bone
The human skeletal system provides an array of functions, including mechanical tasks
such as proving structural support, aiding in locomotion, and protection of internal organs [1]. In
addition, bone function includes metabolic tasks such as serving as a host of growth factors or
other signaling molecules, a reservoir for mineral homeostasis, and an environment for bone
marrow [2]. Bone tissue is composed of approximately 60% inorganic components, 30% organic
components, and 10% water [3]. The inorganic component is mainly low crystallinity
hydroxyapatite, a calcium phosphate mineral substance [3]. Over 90% of the organic matrix of
bone is type I collagen, a triple-helical molecule that provides tensile bone strength. Though
collagen is the most abundant, an array of noncollagenous proteins are also found in the organic
matrix such as proteoglycans, osteocalcin, osteonectin, osteopontin, and a multitude of cytokines
and growth factors [3].
Bones can be categorized by shape, size, and location, and are generally classified by
shape into one of the following groups; long bones such as the femur, short bones including the
carpal and tarsal bones, flat bones such as the skull, and irregular bones which form the vertebrae
and sacrum among other bones. Bone can also be classified by tissue type, the two types being
cortical and cancellous bone. Cortical bone is dense, compact bone that makes up 80% of the
bones mass in the body [1], providing compressive strength. Cortical bone is composed of
osteons. Osteons are columns containing multiple layers of osteoblast and osteocyte bone cells,
surrounding a central Haversian canal. Cancellous bone, also referred to as trabecular or spongy
bone, is similar in matrix composition to cortical bones, but has different structures and
functions. It is able to absorb forces and deforms more easily than cortical bone. Cancellous bone
1

has 50-90% porosity, compared to the 5-10% porosity of cortical bones, resulting in cancellous
bones having a much greater surface area to volume ratio [1]. Due to its porosity, cancellous bone
is much more vascularized than cortical bone, has a higher rate of metabolic activity, and is
remodeled more actively. Rather than osteon columns, cancellous bone is formed from rod and
plate like elements, as well as circular packets of lamellae - organized collagen sheets.
Long bones in particular are comprised of three distinct regions; the diaphysis,
metaphysis, and epiphysis [1]. The diaphysis is a hollow, central shaft comprised of cortical bone
tissue, the epiphysis is the trabecular ends of the bone, while the metaphysis is the trabecular
meshwork in between the two. Both the epiphysis and metaphysis are primary cancellous bone,
surrounded by a thin cortical shell layer [1]. Figure 1.1.1 below details the structure and different
regions of long bones [4].

Figure 1.1.1: The structure and different regions of long bone. The metaphysis is not labeled in
this image.
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Bone tissue contains three primary bone cells; osteoclasts, osteoblasts, and osteocytes.
Osteoclasts are responsible for the resorption of bone. Osteoclasts bind to integrin receptors, and
upon the secretion of hydrogen ions and cathespin K enzymes, dissolves the mineral and
collagen matrix respectively [1]. Osteoblast cells are responsible for the synthesis of new bone
matrices and bone formation [1]. Osteocytes are a subset of bone cells that serve a regulatory
function in the body. They express protein whose function relates to the regulation and exchange
of minerals in bone, as well as the transduction of mechanical bone stresses in biologic activity
[1].

1.2. Fracture Healing
In non-critical size defects, the human body is able to facilitate new bone formation and
the repair of the defect site. Surgery and immobilization are common techniques to expedite
recovery, however bone healing is physiological process. The bone healing process occurs in
three phases; the inflammatory stage, the repair stage, and the remodel stage [5]. The first process
is the inflammatory stage and bone healing is the formation of a hematoma, or a swelling and
collection of clotted blood at the fracture site. Following the formation of the hematoma,
inflammatory cells such as monocytes and macrophages are recruited to the defect site, as well as
mesenchymal stems cells (MSCs) [5]. Fibroblast cells migrate and proliferate at the defect site,
forming granulation tissue. The granulation tissue begins the process of the formation of a
vascular network for the transport of oxygen and nutrients to the wound site.
During the repair stage of fracture healing, fibroblasts continue to lay down a vascular
network, as well as begin to develop into chondroblasts that form cartilage. Osteoclasts begin to
break down the bone matrix in preparation for new bone formation. The differentiation of MSCs
into osteoblasts occurs due to the presence of the growth factor BMP-2, leading to mineralization
3

and woven bone formation, resulting in the formation of a callus surrounding the defect site. At
early stages of callus formation, the bone tissue is very weak, thus immobilization is used as a
mechanical technique to aid in bone formation [5]. The last step in fracture healing, the
remodeling step, is a long term process that restores healed bone to its original shape and
structure. Osteocytes constantly facilitate the resorption of unnecessary bone and formation of
new bone in required locations in response to mechanical cues [5].
1.3. Bone Grafting
The bone healing process is only effective in certain capacities. At certain defect sizes,
the body is unable to stimulate natural bone regeneration and healing. This defect size is
characterized as a critical sized defect, and represents the point at which healing will not
spontaneously occur in the human body. Many factors determine if a defect is critical, such as
age, defect location, health of the bone tissue, and mechanical loads placed on the bone, thus an
exact size of a critical defect is relatively arbitrary to define [7], and is considered any defect large
enough that won’t heal on their own, resulting in a non-union. For the purpose of animal models,
critical size defects have been considered as any deficiency at least 2 times the diameter of the
bone [6]. Any untreated defect that is critically sized will remain non-union, meaning limited
integration of bone around the defect site. One of the most common treatments for a critical sized
defect is the implantation of a bone graft. Bone grafts must meet a certain criteria for effective
healing, such as able to fill the defect site, being biocompatible to ensure it does not elicit an
immune response or rejection, and offer mechanical support while simultaneously serving as a
bioactive substrate to facilitate the formation of new bone between the graft and host bone.
Further, ideal bone grafts should possess the following properties aimed to mimic the natural
bone healing process [8]:
4

Osteogenicity – The presence of osteoblasts or osteoblast progenitor cells, aiding the
formation of new bone and mineralization.
Osteoconductivity – The ability of the scaffold to allow cells to infiltrate into the graft, as
well as attach and proliferate throughout the graft.
Osteoinductivity – An osteoinductive graft stimulates the differentiation of progenitor
cells into osteoblast or osteoclast cells to aid in bone resorption or formation.
1.3.1. Autografts
An autograft is a bone graft that has been harvested from the patient’s own bone tissue.
The most common harvesting locations are from the patient’s iliac crest due to its density and
non-essential functions, as well as mandibular bone for facial grafts. Due to native tissue being
used, autografts will not be rejected or cause a foreign body response. Autografts are seen as the
current gold standard for bone grafting, due to their biocompatibility, as well as their retention of
naturally occurring bone cells and proteins [9]. The porous nature of the harvested bone retains
osteoconductive properties, while these cells and proteins that remain in the graft result in a bone
substitute that is osteoinductive and osteogenic [8], and will contribute to bridging and new bone
formation.
Though autografts remain the gold standard for bone grafting, they introduce a variety of
setbacks and shortcomings. The primary drawback is additional donor site morbidity at the site
of harvested bone. This has the potential to lead to longer recovery time, increased risk of
infection, or an increased risk of other complications. Additionally, because tissue is harvested
from the patient themselves, there is a limited supply available, and furthermore an autograft
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becomes impossible to use for very large sized defects, as it is not reasonable to take a large
portion of the patients own bone to fill the defect site.

1.3.2. Allografts
The use of allografts addresses the current shortcomings of autografts. Allografts are the
main focus of this research, and are bone grafts that are harvested from a separate human donor,
mainly a cadaver. The allografts harvested are typically taken from the same location as an
autograft, however due to the use of cadaveric donors, additional donor site morbidity and
limited supply is not an issue. Moreover, the number of harvest locations increases in a cadaveric
donor, as there is less of a need to harvest non-essential bones. While allografts address the
shortcomings of autografts, they introduce a variety of issues that prevent them from being the
gold standard used in bone grafting. For instance, biocompatibility is a concern with allograft
implantation, ensuring that the graft does not elicit an immune response or become rejected [10].
A related concern is the rare transmission of disease or contaminants as well through allograft
implantation. In order to guarantee there is no immune rejection or disease transmission,
allografts are often sterilized prior to implantation, typically using ethylene oxide, radiation, or
an autoclave [11]. However, the side effect of the sterilization process is the loss of natural bone
cells and proteins that generate new bone formation. This causes allografts to lose their
osteogenic as well as osteoinductive properties [8]. Due to the loss of osteogenic and
osteoinductive components, the natural healing process and union of the host bone and the graft
is less likely, resulting in a large percent of long term failures and complications [12]. Up to 60%
of cortical allografts have reported failures or complications after 10 years post-implantation, as
well as a 50% loss in allograft tissue strength in the same time period [12]. This is thought to be
6

due to the bone graft’s inability to fully bridge between the graft and host bone, and not fully
achieving the natural process of bone healing. The current research focuses on methods to
revitalize allografts, to improve their bioactivity and bone healing, to ultimately lead to a greater
long term success rate.
1.4. Growth Factors
The processes of bone healing are initiated and stimulated by the release of growth
factors. Growth factors are proteins that are secreted by a signaling cell to elicit a specific
response. Growth factors bind to their respective cellular receptors causing a cascade of signaling
to produce a response. In bone healing, vascularization and new bone formation are the two main
aims for wound site repair. These events are driven by the secretion of angiogenic and osteogenic
growth factors respectively [13].
Osteogenesis is the process of new bone formation. The growth factors that are the most
crucial in this step are the bone morphogenetic proteins (BMPs). BMP-2 and BMP-7 are the
commonly used and studied BMPs, and both are currently available in certain clinical
applications [14]. BMPs are classified under the TGFβs family, and influence many different
events during the bone healing process, mainly stimulating the formation of new bone. BMPs
elicit the proliferation and differentiation of osteoprogenitor cells from mesenchymal stem cells
(MSCs). The MSCs are then differentiated into osteoblasts and osteocytes, which form
mineralized woven bone, as well as maintain bone tissue homeostasis respectively. Additionally,
BMPs stimulate chemotaxis, which promotes the formation of cartilage and new bone.
Osteogenic and angiogenic growth factors have shown to have synergistic effects when delivered
together, one example showing that BMPs also aid in the synthesis of extracellular matrices and
are seen during the stages of angiogenesis.
7

Angiogenesis is the process of forming new blood vessels, and is critical in bone repair,
and one of the initial events that occurs. Newly formed blood vessels allow the access of
nutrients, oxygen, and cells to the defect site, as well as a method for the removal of metabolic
waste. Without this step, bone formation becomes more difficult and delayed union or non-union
is much more likely, as seen in research that showed limited bone formation in groups without
angiogenic growth factors present [38]. Angiogenesis is stimulated by a variety of signaling
growth factors. One angiogenic growth factor is fibroblast growth factor (FGF). FGF stimulates
proliferation and differentiation into endothelial and smooth muscle cells that are essential for
new blood vessel formation. Another angiogenic growth factor, VEGF, is thought to be of the
most important growth factor to stimulate new vessel formation. VEGF is present in 4 different
isoforms: A, B, C, D, however VEGF-A has been studied as the most significant for
angiogenesis. VEGF is secreted and is present throughout many steps of the natural bone healing
process. VEGF is seen in early stages of wound healing, as a role of vascularizing bone tissue
from a cartilaginous matrix. VEGF in combination with angiopoietin causes the formation and
differentiation of mature blood vessels at the wound site. However as previously stated, VEGF is
an angiogenic growth factor that has synergistic results when used in combination with
osteogenic growth factors [16]. VEGF receptors are found on many cells related to the process of
bone formation, such as osteoblasts and osteoclasts. VEGF can bind to these receptors to
increase blood vessel density at their location. Additionally, VEGF in combination with
RANKL, stimulates the differentiation of progenitor cells into osteoclasts in vitro [41, 42], which
are later present in the resorption of bone and osteoclastogenesis, a key process in bone
remodeling. The table below based on [17] details the growth factors and cytokines that are
present in the natural bone healing response.
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Cytokines/Growth Factors


Interleukin-1, 6 (IL)





Bone healing stages

Overall action


Hematoma

Tumor necrosis factor α



Inflammation

(TNF)



MSCs recruitment



Chondrogenesis

factors (VEGF)



Endochondral ossification

Bone morphogenetic growth



Osteoblast/Osteoclast

1.Inflammation

Platelet-derived growth
factors (PDGF)



Growth differentiation factor8 (GDF)



RANKL, macrophage
colony-stimulating factor (MCSF)



Osteoprotegerin



Vascular endothelial growth



2.Cartilage Formation

factors (BMP)


precursors recruitment

Transforming growth factor



Vascular ingrowth

βs (TGF)



New angiogenesis



Angiopoietin



Fibroblast growth factors
(FGF)



VEGFs

3.Cartilage resorption and primary bone



Chondrocyte apoptosis



BMP-2, 7

formation



Cartilage resorption



RANKL and M-CSF



Osteoblast/Osteoclast



Angiopoietin

precursors differentiation


Woven bone formation



IL-1, IL-6

4.Secondary bone formation and



Bone remodeling



RANKL and M-CSF

remodeling



Osteoblast activity



Marrow establishment

Table 1.4.1: Growth factors and cytokines and their roles in natural bone healing.
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1.5. Growth Factor Loading for Delivery
The goal of successful tissue engineering applications is to mimic the natural biological
response for the specific tissue healing type. Due to growth factor secretion being a key aspect of
natural bone healing, incorporating growth factors into a bone graft system has the potential to
increase the bioactivity and wound healing on the graft. The growth factors must be attached to
the graft in a manner that can protect the growth factor from degrading in the body prior to being
effective. VEGF has an estimated half-life of 30 minutes [18], while the half-life of BMP-2 has
been determined to be up to 16 minutes in animal models [19] when administered intravenously.
As a result, the dosage used often exceeds physiological levels of the natural growth factor, and
can lead to ectopic vessel and bone formation in the non-target area [18, 31, 32]. Thus, the desired
design is to load the growth factors to the graft in a manner that protects them from degradation,
and provides sustained release of the growth factor, eliminating the need for exceeding dosages
to elicit a response.
One method to incorporate growth factors or proteins in a system, and the method used in
this research, is to integrate them into a degradable polymer coating. Polymer coatings can be
synthesized with varying properties, to alter and control degradation rates. Poly(lactic-coglycolic acid) (PLGA) was the polymer of choice for the allograft coating for a variety of
reasons; including its FDA approval, affinity to surface bind proteins, as well as its controllable
degradation, allowing for long term sustained delivery [37]. In addition to long term delivery,
proteins released from PLGA show biphasic behavior, with an initial burst release from
interactions with its surrounding media, as well as the extended, sustained release from
degradation via hydrolysis [37]. The release kinetics of therapeutic agents from PLGA can also be
altered by varying the drug concentration, polymer concentration, molecular weight, ratio of
10

lactic acid to glycolic acid, as well as the methodology of protein loading, hypothesizing that the
physical amount of growth factor released can be controlled with different PLGA parameters, a
significant aspect for potential future clinical applications.
Two strategies to load growth factors or other therapeutic agents within a polymer coating is
through physical encapsulation or surface adsorption. Growth factors or agents can be physically
encapsulated to a scaffold, by mixing the drug solution with the polymer solution prior to the
synthesis of the scaffold. This method will release the entrapped drugs as the polymer degrades,
thus release kinetics can be altered by varying the degradation rate of the polymer. For instance,
PLGA, a copolymer of polylactic acid (PLA) and polyglycolide (PGA) can have varying
degradation rates based on the ratio of PLA to PGA [20], and additional factors such as molecular
weight or polymer concentration can also vary degradation times. Another method of loading
growth factors or other proteins onto a scaffold is through surface adsorption. This technique is
completed by the incorporation of the drug solution to the preexisting scaffold, attaching the
growth factor directly to the surface of the polymer scaffold. The main mechanism behind drug
release in this case is diffusion. This results in a burst release of polymer, as the proteins on the
surface of the scaffold desorb at a rate based on solubility and molecular weight, allowing for a
more immediate delivery and availability of the growth factor or therapeutic agent.
1.6. Bone Infection
Bone infection, or osteomyelitis is a common concern post-surgery. It causes the
inflammation of bone tissue, which can hinder the recovery and healing process. Patients are at
an elevated risk of developing osteomyelitis post-surgery. Thus, there is a benefit to being able to
incorporate and controllably release antibiotics to the surgical site, to prevent infection or fight
infection that begins to develop. Furthermore, common osteomyelitis treatment protocols suggest
11

4 to 6 weeks of antibiotic usage [21, 22], and additionally it has been determined that local
administration of antibiotics had lesser instances of side effect reactions that systemic
administration, while still demonstrating comparable treatments [23]. Thus, the long term local
delivery of antibiotics is an aspect of bone grafting that is addressed in this current research. A
common method of antibiotic release is the use of poly(methylmethacrylate) (PMMA) beads
containing antibiotics [23], however the non-degradable nature of the beads has gathered concerns
about toxicity or future complications, and release patterns were shown to be erratic and noncontrollable. Release kinetics of antibiotics should be aimed to mimic the current treatment of
antibiotics following surgery. Antibiotic treatment is started immediately in the operating room,
and often preventative antibiotics are given prior to surgery [24]. While long term controlled
delivery will follow in accordance with the 4 to 6 week treatment protocol, burst release of
antibiotics will mimic the treatment given in the operating room, and provide antibiotic release
immediately upon graft implantation. The antibiotic used in these studies is gentamicin.
Gentamicin is effective against many bacterial infections, particularly gram negative infection
[25].

It is an aminoglycoside antibiotic, which inhibits bacteria from synthesizing protein [25]. Side

effects of gentamicin include nerve, ear, and kidney problem [25], thus the controlled local release
of gentamicin is beneficial for reducing side effects while maintaining the therapeutic efficacy.
1.7. Specific Aims
The project was broken down into 4 specific aims. The first specific aim was to
characterize and qualitatively assess the polymer degradation in vitro of the PLGA coated
allografts. This was used in conjunction with release studies to verify and observe the
relationship between polymer degradation and drug release. Specific aim 2 was to analyze the
release kinetics of encapsulated BMP-2 using various polymer concentrations. The goal was to
12

show how varying the coating parameters would alter the amount of drug released, as well as
show encapsulated BMP-2 was able to continue to provide sustained, long term release after a
slight burst effect. The objective of specific aim 3 was to compare the release kinetics of both
encapsulated and surface adsorbed gentamicin from varying polymer concentrations. The
multiple concentrations would again be compared to assess the controllability of the allograft, as
well as attempt to achieve the desired release kinetics over 4 to 6 weeks of controlled gentamicin
delivery, in addition to the burst effect to immediately begin to fight and prevent infection. The
final specific aim was to observe wound healing upon allograft implantation in vivo. Within the
scope of this project, qualitative results only were analyzed from an in vivo animal study headed
up by Farzana Sharmin, a PhD candidate. Femoral segmental defects were made in rat models,
where control allografts, allografts encapsulated with BMP-2, and allografts with a dual coating
of encapsulated BMP-2 and surface adsorbed VEGF were implanted, and wound healing was
compared between the 3 groups using X-ray imaging and MicroCT.
1.8. Preliminary Studies
Preliminary studies for this research were done by last year’s Master’s student Casey
McDermott, and his research and results are summarized in this section. Two PLGA coating
techniques were performed, and SEM imaging and MicroCT were used to determine which
coating method resulted in a more continuous and uniform coating that was able to coat not only
the surface of the allograft, but within the porous network as well. A static technique was
employed, by submerging the cancellous allografts in a 50:50 ratio (PLA:PGA) PLGA solution
for 24 hours, followed by 24 hours of solvent evaporation, concluded with 24 hours of
lyophilization. A dynamic method followed similar techniques, however for the first 24 hours of
coating, the allografts were placed in a rotating rocker machine, for continuous 3D motion,
13

following by the same evaporation and lyophilization process. The dynamic coating method is
explaining in further detail in section 2.1. X-ray and MicroCT imaging were used to assess the
extent and volume of the coating.

Figure 1.8.1: MicroCT imaging of PLGA coating volume of dynamically coated allografts (left),
vs. a static coating (right).
MicroCT imaging in figure 1.8.1 shows the dynamic coating method proved to be superior to the
static coating, with the PLGA coating being more consistent and penetrating throughout a larger
extent of the porous allograft than the static coating. The static coating resulted in a much less
extensive coating, with roughly half the allograft left as uncoated bone.
In addition to the coating method, SEM imaging and MicroCT were used to determine
optimal polymer concentrations for the coating. A range of polymer concentrations were tested,
with MicroCT quantifying the coating volume for each. There was a consistent trend of a more
concentrated polymer solution resulted in more coating volume, as shown in table 1.8.1 below.
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Polymer Concentration
Coating Volume
g/ml
mm^3
77.9
1:10
1:12
72.2
1:14
72
1:16
62
1:18
53
1:20
47
Table 1.8.1: Effect on Coating Volume due to change in PLGA concentration
SEM imaging was used to further analyze polymer concentrations of 1:12, 1:14, and 1:20. Figure
1.8.1 shows the SEM images for the 1:12 PLGA concentration. The coating was able to
effectively extend through the allograft, however it can be seen in figure 1.8.1-B that the
concentration was high enough that it began to block the natural porous architecture of the bone.

Figure 1.8.2: SEM image of dynamically coated cancellous allograft using PLGA concentration
of 1:12. A) x37 magnification, B) x80 magnification
Similarly SEM imaging for concentrations of 1:14 and 1:20 PLGA were analyzed. Figure 1.8.3
shows that the 1:14 PLGA concentration was able to extend throughout the allograft while
leaving the porosity of the bone largely unaffected, and was determined to be the ideal balance of
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coating extension and retention of the allografts porous properties. Figure 1.8.4 displays that the
polymer concentration was relatively thin, and portions of uncoated bone remain.

Figure 1.8.3: SEM image of dynamically coated cancellous allograft using PLGA concentration
of 1:14. A) x30 magnification, B) x80 magnification

Figure 1.8.4: SEM image of dynamically coated cancellous allograft using PLGA concentration
of 1:20. A) x37 magnification, B) x80 magnification
VEGF was surface adsorbed for 15 minutes at a concentration of 5 μg/ml onto the surface
of the allografts at polymer concentrations (grams PLGA/ml tetrahydrofuran) of 1:8, 1:14, and
1:20, with a n = 4. The cumulative amount of VEGF released was consistent with the results of
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the polymer coating volume characterization. A larger coating volume would result in more
growth factor being able to attach and bind to the polymer, thus a larger release. Figure 1.8.5
depicts this relationship, as more growth factor was release with higher PLGA concentrations.
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Figure 1.8.5: Cumulative release of surface adsorbed VEGF from PLGA coated allografts at
concentrations of 1:8, 1:14, and 1:20.
The release kinetics of the surface adsorbed VEGF showed a large burst release, with all 3
polymer concentrations releasing greater than 85% of their total release after day 1. After day 3,
little continuous release is observed for all polymers, and eventually plateaus by the end of week
1.
BMP-2 was both surface adsorbed at 50 μg/ml and encapsulated at 67 μg/ml in polymer
concentrations of 1:8 and 1:14 respectively. Surface adsorbed BMP-2 followed similar release
kinetics as VEGF, though to a much more drastic extent.

17

Cumulative BMP-2 Concentration
BMP-2 conc. (ng/ml)

120
100
80
60
40
20
0
0

20

40

60

80

100

120

140

160

180

Time (hours)

Figure 1.8.6: Cumulative release of surface adsorbed BMP-2 from PLGA coated allografts at a
concentration of 1:8
As the image above shows, 100% of BMP-2 was released by the end of the first day, followed by
an immediate plateau with no observed gradual release afterwards. Surface adsorbed release is
dictated through diffusion, and BMP-2’s smaller molecular weight compared to VEGF caused a
much more significant burst release. A release of encapsulated BMP-2 was measured throughout
the duration of 3 weeks. A burst release was observed within the first day, but to a lesser extent
than the surface adsorbed loading. The BMP-2 was continuing to demonstrate sustained release,
even by the end of the 3 week period.
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Figure 1.8.7: Cumulative release of encapsulated BMP-2 from PLGA coated allografts at a
concentration of 1:14
Finally, gentamicin was surface adsorbed on allografts with a PLGA concentration of
1:14. Following the trend of surface adsorbed release, over 70% of gentamicin was released
within the first day, half of that release occurring within the first few hours. The gentamicin
continued to release for the duration of the first week, similar to the surface adsorbed VEGF, and
did not appear to be at a plateau by the end of the study.
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Figure 1.8.8: Cumulative release of surface adsorbed gentamicin from PLGA coated allografts
at a concentration of 1:14
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Materials and Methods
2.1. Polymer Coating
The entirety of the allograft coatings were completed using the following procedure,
referred to as the dynamic coating procedure. Cancellous canine allografts were obtained from
Veterinary Transplant Services, Inc. with dimensions of 1.0 cm x 1.0 cm x 0.5 cm ± 0.2 cm. The
samples were cut in half width-wise for final estimated dimensions of 1.0 cm x 0.5 cm x 0.5 cm.
The allografts were stored in a -20° C freezer. Poly(lactic-co-glycolic acid), PLGA, was
purchased from Lakeshore Biomaterials, in a solid, crystal pellet form, and stored at -20° C.
To coat the allografts, both the PLGA and allografts were brought to room temperature
prior to coating. The PLGA was dissolved in tetrahydrofuran (THF) at different amounts to
obtain a desired concentration of PLGA solution in g PLGA/ml THF. The PLGA was dissolved
in a vortex machine until no solid pellets remained and the solution was homogeneous.
Allografts were weighed prior to coating, and then placed in a 5 mm syringe. The polymer
solution was then pushed and expelled through the syringe containing the allograft a total of 10
times, repeated twice. The allografts were then submerged in approximately 2 ml of polymer
solution inside a closed vial, and placed in a Labquake Rotisserie Rocker from Thermo
Scientific, allowing the allografts to be continuously rotated, as well as constantly agitated in the
polymer solution throughout the coating process. The goal of this design was to achieve
continuous coating throughout the allograft, specifically a coating that extended throughout the
porous nature of the cancellous allograft. After 24 hours in the rocker, the caps were removed
from the vial to allow the solvent to evaporate from the polymer solution, and the rocker was
placed at an angle to allow rotation without spilling any solution. After at least 24 hours to
ensure all the solvent had evaporated, the samples were lyophilized for an additional 24 hours to
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ensure the complete drying of the samples, upon which the samples were weighted again to
calculate the total mass of the polymer coating.
2.2. Polymer Degradation Characterization
Allografts were characterized qualitatively using SEM imaging to observe and analyze
the degradation kinetics of the PLGA coating over time. 10 cortical allografts were harvested
from the long bones of retired breeder rats, and dynamically coated with a PLGA concentration
of 1:8, with one bone serving as a control allograft with no PLGA coating. No growth factor or
other proteins were added to the polymer solution. After lyophilization, the allografts were
submerged in PBS at 37° C for the following time points; 1 day, 3 days, 5 days, 7 days, 2 weeks,
3 weeks, 4 weeks, 5 weeks, and 6 weeks. At the corresponding time point, the allograft was
removed from the PBS solution and lyophilized to ensure the complete drying of the sample
prior to SEM imaging.
The allografts were cut in half with a blade, and placed on the SEM sample stage
platform using an adhesive strip, in a manner that allowed viewing of the surface and crosssectional views of the allograft. The allografts were sputter coated using gold-palladium to
prevent the charging of the samples, and placed in the SEM. Multiple views were captured from
each sample in order to view the entire allograft. The amount of PLGA coating on the allografts
was compared to control images to qualitatively assess the PLGA degradation over time in vitro.
2.3. BMP-2 Release Study
2.3.1. Loading of BMP-2
The release of the growth factor protein BMP-2 was tested via encapsulation. A 500 μg
vial of recombinant human BMP-2 powder was purchased from Fisher Scientific, and stored at
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-60° C prior to use. Glacial acetic acid was diluted with DI water to a solution of 20 mM acetic
acid, 500 μl of which was used to reconstitute the BMP-2 powder. PLGA was dissolved in THF
at three different concentrations; 1:8, 1:14, and 1:20 g PLGA/ml THF. Once the polymer
solutions were fully homogeneous, 500 μl of reconstituted BMP-2 solution was slowly added to
each individual polymer solution, 100 μl at a time, to avoid any precipitation. The theoretical
loading concentration was 67 μg/ μl. Control allografts were additionally coated by adding 500
μl of just 20 mM acetic acid at the same rate, to separate polymer solutions of 1:8, 1:14, and
1:20. Upon fully adding the BMP-2 solution, allografts were coated using the dynamic
procedure. A total of n = 4 allografts were tested for each polymer solution.
2.3.2. BMP-2 Release
The allografts were placed in a 4x6 well plate, with one allograft per well. The allografts
were immersed in 1.5 ml of PBS and the well plate was wrapped in parafilm to reduce PBS
evaporation. The allografts were placed in a 37° C room, to simulate the temperature, pH, and
ionic concentrations of the human body. At specific time point intervals, the supernatant fluid
was collected and stored at -20 ° C, and the allografts were moved to a new well and resubmerged in PBS. The time points taken were hours 1, 2, 4, 8, 12, and days 1, 3, 5, 7, 10, 14,
21, 28, 35, and 42 for the 1:14 and 1:20 polymer concentrations, while the 1:8 polymer
concentration had time points taken up to the 28 days.
2.3.4. BMP-2 Analysis
BMP-2 samples were quantified via an enzyme-linked immunosorbent assay (ELISA),
purchased from R&D Systems. The ELISA kit measures the concentration of BMP-2 present in
each sample collected from the release study. Using the BMP-2 standard from the kit, standard
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BMP-2 concentrations of 4000 pg/ml, 2000 pg/ml, 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125
pg/ml, 62.5 pg/ml, and 0 pg/ml were created. 100 μl of Assay Diluent was added to each well of
the 96 well microplate, followed by 50 μl of either the sample, control, or standard. The plate
was covered with an adhesive strip and placed on a shaker for 2 hours at room temperature. 400
μl of Wash Buffer was added to each well and then aspirated, for a total of 4 washes. 200 μl of
BMP-2 Conjugate was added to each well, incubated for an additional 2 hours, and then the wash
process was repeated. 200 μl of Substrate Solution was added and covered from light at room
temperature for 30 minutes, followed by the addition of 50 μl of stop solution. The plates were
read using a BioTek Synergy HT plate reader at wavelengths of 450 nm and 540 nm.
2.4. Gentamicin Release Study
2.4.1. Surface Adsorption of Gentamicin
Two separate PLGA solutions were created to test the release of surface adsorbed
gentamicin, 1:14 and 1:20. PLGA was dissolved in THF to obtain the desired concentration, and
coated following the previously mentioned dynamic coating procedure, for a total of n = 4
allografts and 4 controls for each polymer solution. Gentamicin was loaded onto the allografts
via surface adsorption. Gentamicin was purchased from Sigma-Aldrich, as a stock solution of 10
mg/ml and was stored at a temperature of 4° C. The gentamicin solution was diluted with
deionized water to a loading concentration of 100 μg/ml. The coated allografts were removed
from the lyophilizer, and organized such that 4 bones of each polymer solution would be loaded
with gentamicin, and the remaining 4 would serve as control groups. The experimental allografts
were completely submerged in 1 ml of the gentamicin solution for 15 minutes at room
temperature, while the control allografts were submerged in DI water following the same
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parameters. The allografts were stored at a temperature of -20° C for 24 hours, followed by 24
hours of lyophilization.
2.4.2. Encapsulation of Gentamicin
Gentamicin was additionally encapsulated in a 1:14 polymer solution, to compare the
release kinetics with that of the surface adsorbed gentamicin, as well as determine if
encapsulated gentamicin and BMP-2 showed similar kinetics. PLGA was dissolved in THF to
obtain the two distinct polymer concentrations and an n = 4. The stock solution of gentamicin
was diluted with DI water to a concentration of 800 μg/ml, and 500 μl was added to the polymer
solution 100 μl at a time. A control group was created by adding 500 μl of DI water at the same
rate to a separate vial also containing a 1:14 polymer concentration. The allografts were coated
using the dynamic method, with an approximate loading concentration of 50 μg/ μl.
2.4.3. Gentamicin Release
Gentamicin was released with the same procedure as BMP-2. Allografts were placed in
the wells of a 24 well plate, submerged in 1.5 ml of PBS, and stored in the 37° C room. The
supernatant fluid was collected and stored at -20° C prior to analysis, and time points were taken
at hours 1, 2, 4, 8, 12, and days 1, 3, 5, 7, 10, 14, 21, 28, 35, and 42.
2.4.4. Gentamicin Analysis
The samples were removed from the -20° C freezer, and set at room temperature to
gradually thaw. The gentamicin stock solution was diluted with PBS to obtain .5 ml of
concentrations of 320 μg/ml, 160 μg/ml, 80 μg/ml, 40 μg/ml, 20 μg/ml, 10 μg/ml, 5 μg/ml, and
pure PBS, to be used later to establish a standard curve for gentamicin. A gentamicin reagent was
made to bind to the amino groups of the gentamicin samples, allowing them to be quantified via
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spectrophotometry. 2-propanol, o-phthaldialdehyde, and 2-mercaptoethanol were purchased from
Sigma-Aldrich. 0.25 grams of o-phthaldialdehyde, 6.25 ml of methanol, and 300 μl of 2mercaptoethanol were added to 56 ml of a .04 sodium borate solution. The resulting solution was
protected from light and stored for 24 hours prior to use. When the gentamicin samples were
thawed, 100 μl of each the sample, reagent, and 2-propanol were added to an individual well of a
96 well plate, including the 8 standard samples. The propanol was added to prevent the
precipitation of products being formed. The well plates were then stored for 45 minutes, and then
read using a BioTek Synergy HT plate reader at a wavelength of 332 nm. Using the absorbance
readings for the samples with known concentration, a standard curve was created and used to
determine the concentration of the samples.
The data figures for both gentamicin as well as BMP-2 are presented as the mean
cumulative release from a sample size of n = 4, and all error bars represent the standard deviation
of the data.
2.5. In Vivo Evaluation of Dually Loaded Allografts
2.5.1. Allograft Preparation
Cortical allografts approximately 6 mm in length were coated with PLGA at a ratio of
1:8. 3 different experimental groups with an n= 4 were organized; control allografts containing
no coating, BMP-2 only allografts containing encapsulated BMP-2, and dually loaded allografts
containing encapsulated BMP-2 and surface adsorbed VEGF. The loading concentration of the
BMP-2 allografts was approximately 300 ng/ml, while the loading concentration of VEGF was
approximately 180 ng/ml. BMP-2 was reconstituted using 20 mM acetic acid, while VEGF was
reconstituted using DI water. The coating and encapsulation only procedures followed the
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similar steps as previously described. The dually coated group was first encapsulated with the
BMP-2 solution. After lyophilization, samples were placed in an ice bath, from which they were
surface adsorbed in the VEGF solution as previously described.
2.5.2. In vivo Defect and Allograft Implantation
10 week old male Sprague-Dawley rats weighing in a range of 300-325 grams were used
in the in vivo implantation of the allografts. All procedures were performed in accordance with
approved Institutional Animal Care and Use Committee guidelines. The right forelimb of the rat
was shaved and sterilized with betadine and 70% ethanol. An incision was made through the skin
and periosteum of the rat, and a 6 mm critical sized defect was created in the femur. A small
plate was attached to the femur via Kirchner wires and steel cerclage wires to stabilize the femur
during the procedure. The allografts were then fit into the defect site, and fixed in place with the
use of a single 4-0 Vicryl (Ehticon, Somerville, NJ) cerclage stich. The 4-0 sutures were used to
close the muscle, subcutaneous tissue, and skin. The rats were sacrificed at 4 and 8 weeks postsurgery, upon which the femurs were harvested and stripped of the metal pins and sutures, and
fixed in 70% ethanol at 4° C prior to analysis. Figure 2.5.2.1 below visualizes this process.
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Figure 2.5.2.1: Surgical procedure of allograft implantation. The rat leg is prepped by shaving
and washing with betadine and 70% ethanol (A). The rat leg and muscle is incised (B). A
polyethylene plate is pressed up to the femur (C). Kirschner wires are used to fix the plate to the
femur (D). Surgical wires are used to further secure the plate to the bone (E). Allografts cut to
approximately 6 mm are measured to approximate the desired defect site size (F). A defect is
created in the femur using a dremel (G). The allograft is press fit in the defect site (H). 4-0
sutures are used to secure the allograft to the plate and in the defect site (I). The muscle, tissue,
and skin are stitched back together (J).
2.5.3. X-Ray Analysis
Femurs were analyzed using a Faxitron X-ray machine with its corresponding Faxitron
DC-Beta SR v1.4 software. Images of each femur were taken at 26 kV for 6 seconds.
2.5.4. MicroCT Analysis
Three-dimensional views of the defect site were recreated using micro-focus X-ray
computed tomography (μCT40, Scanco Medical AG, Basserdorf, Switzerland.) The defect site
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was viewed between the two pin holes, at 55 kV and 145 μA with a 300 millisecond integration
time.
3 Results
3.1. SEM Characterization of Polymer Degradation
Polymer coated cortical allografts were analyzed qualitatively, using topographical
images from an SEM scan. Cortical allografts were coated with a PLGA solution of 1:8, and
submerged in PBS at 37 °C. The allografts were cut in half to allowing viewing of surface and
cross-section of the bone. Images were taken from allografts submerged in PBS for varying time
points, to assess the degradation process of the polymer coating over time, shown in figure 3.1.1.
In the SEM scans, uncoated bone is seen as slightly brighter in the image, and has a
jagged appearance, seen in figure 3.1.1 (a). The PLGA coating appears smoother, and a slightly
darker color, most evident in figure 3.1.1 (b). Allografts submerged for three days showed a very
large percentage of the surface bone coated with PLGA, while images of subsequent time points
showed gradually less polymer coating, and more uncoated bone as the polymer began to
degrade in the PBS. By day 42, very little polymer is seen even in the more magnified image,
indicating almost all PLGA had degraded in the PBS. For each time point, there was a consistent
trend showing the surface of the allograft contained slightly more coating than the cross section.
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Figure 3.1.1: Surface views of PLGA coated allografts. Uncoated bone is shown in (A). B
through I represent days 3, 5, 7, 14, 21, 28, 35, and 42 respectively. Throughout the duration of
the study, SEM imaging shows less polymer coating present, and more uncoated bone,
displaying the degradation kinetics of the coated allografts.
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Figure 3.1.2: Cross sectional views of PLGA coated allografts. Uncoated cross sectional bone is
shown in (A), while B through I represent days 3, 5, 7, 14, 21, 28, 35, 42 respectively. The
PLGA degrades in a similar manner over time as the surface view, with more uncoated bone
present the later the time point is. However, less PLGA coating is seen in the cross sectional
views in general compared to the surface coating.
3.2. Analysis of Encapsulated BMP-2
Cancellous allografts with an n = 4 were coated with 1:8, 1:14 and 1:20 PLGA coatings,
with BMP-2 physically encapsulated in the polymer solution. The growth factor exhibited burst
release, with 82%, 67%, and 53% of the BMP-2 being released in the first 24 hours for the 1:8,
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1:14 and 1:20 concentrations respectively. However, the allografts maintained an extended
release of the protein as well, with steady release shown over 4 weeks, with an eventual plateau
of growth factor released by day 42. The PLGA concentration of 1:8 is currently at the 4 week
time point, thus 42 full days of release had not been calculated to determine the extent of
sustained release. The total cumulative release concentration of BMP-2 from the 1:14 coated
allografts was 92 ng/ml, and 33 ng/ml from the 1:20. The current 14 day cumulative release of
BMP-2 from the 1:8 PLGA concentration is 130 ng/ml.
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Figure 3.2.2: Release of encapsulated BMP-2 from 1:8, 1:14, and 1:20 PLGA concentrations.
Release is sustained and continues until 42 days in the case of the two later polymer
concentrations, after an initial burst release
3.3. Analysis of Encapsulated Gentamicin
Gentamicin was encapsulated in PLGA with a 1:14 ratio, and used to coat cancellous
allografts with an n = 4. Gentamicin was diluted down from its stock solution, and added to the
PLGA solution prior to coating. The antibiotic was released in PBS at 37°C for 6 weeks. By the
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end of the first day, 63% of the gentamicin was released, however there was a steady release of
gentamicin up until week 4. The cumulative release concentration was 118 μg/ml. Figure 3.3.1
depicts the encapsulated gentamicin release kinetics, and figure 3.3.2 compares the percent
release of encapsulated gentamicin and BMP-2 from 1:14 PLGA. The two curves show very
similar release kinetics of the two encapsulated molecules. BMP-2 and gentamicin both showed
a burst release of 67% and 63% in the first day respectively, and both achieved 100% release by
day 35.
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Figure 3.3.1: Release of encapsulated gentamicin from 1:14 PLGA coated allografts. Release
appears to be sustained for up to 21 days, after which release begins to plateau.
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Figure 3.3.2: Percentage released of BMP-2 and gentamicin from 1:14 PLGA coated allografts.
The release kinetics appear to be comparable in terms of burst release and total release time.
3.4. Analysis of Surface Adsorbed Gentamicin
Gentamicin was also loaded onto the cancellous allografts via surface adsorption, at
polymer concentrations of 1:14 and 1:20. Both polymer concentrations showed similar release
kinetics, seen in figure 3.4.1. The kinetics began as a burst release, followed by a plateau in
release – the expected trend observed for surface adsorbed agents. However at day 10 and 14,
there was additional release from the 1:20 and 1:14 PLGA respectively, followed by another
plateau. Because of this additional release, the relative burst release was not as significant as
seen in the surface adsorbed VEGF from the preliminary studies, in this case only 56% and 62%
of gentamicin was delivered from the 1:14 and 1:20. More gentamicin was available from the
higher polymer concentration, with cumulative release values of 292 μg/ml and 44 μg/ml for
1:14 and 1:20 PLGA respectively.
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Figure 3.4.1. Release kinetics of surface adsorbed gentamicin from 1:14 and 1:20 PLGA. Both
release curves showed burst release followed by a plateau, as well as a period of additional
release in the middle of the release time period.
Figure 3.4.2 additionally shows the relationship between both encapsulated and surface adsorbed
gentamicin released from 1:14 PLGA, portrayed non-cumulatively. As the figure shows, surface
adsorbed release allows for a greater availability of the drug within the first 1 – 7 days, however
after 1 week there is no more gentamicin to be released. On the other hand, encapsulated
gentamicin has a much lower amount available within the first week, however as the surface
adsorbed gentamicin completed its release, encapsulated gentamicin began to sustainable release
for a longer period of time.
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Figure 3.4.2: Release kinetics of both surface adsorbed and encapsulated gentamicin from 1:14
PLGA. Surface adsorbed gentamicin showed more gentamicin available in the first week, while
encapsulated gentamicin showed less available, however a more long term sustained release.
3.5. In Vivo X-ray Analysis
X-ray radiographs were taken throughout the healing process to assess the new bone
formation in the control groups, BMP-2 alone, and BMP-2 and VEGF groups. Figure 3.5.1
shows the control allograft after 4 weeks of healing. The image shows no indication of callus
formation or mineralization formed at the defect site, indicating the allograft implantation was
non-union at the defect site. Radiograph images were also taken and analyzed every 2 weeks
post-implantation. Figure 3.5.2 displays the bone formation observed throughout the course of
the healing process.
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Figure 3.5.1: X-ray radiograph of the control allograft after 4 weeks of implantation. No healing
or bone bridging is observed.

Figure 3.5.2: Radiograph images taken every 2 weeks post-implantation, to compare BMP-2
alone to a combination of BMP-2 and VEGF.
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Bone bridging is seen in the image as the new opaque formation above the allograft in the defect
site, indicating potential mineralization and bone formation is occurring due to bridging. The
dually loaded allograft shows nearly complete bridging of the ends of the allograft and host bone
due to new bone formation by week 8, suggesting the allograft forms a near complete union at
the defect site. In the BMP-2 and VEGF group, callus formation and bridging are first observed
in the radiographs at week 4. At week 4, 6, and 8, increased mineralization and bridging are seen
throughout the increasing healing time in both groups, however the dually loaded allograft shows
slightly augmented bridging compared to BMP-2 alone. The BMP-2 alone group shows
enhanced callus formation compared to the control bone by the week 4 time point.
3.6. MicroCT Analysis
MicroCT imaging was done at 4 and 8 weeks post-implantation. MicroCT images and
radiographs were taken to further verify callus and bone formation at the defect site. MicroCT
radiographs confirmed the X-ray images, demonstrating that bone bridging and mineralized
callus formation was enhanced for the dually loaded allograft compared to both the BMP-2 alone
at week 4, and both groups showed callus formation and some bone bridging. Compared to the
control group, both growth factor loaded allografts show enhanced callus formation, as seen in
figure 3.6.1. 3D images of the allograft implantation at the defect site were rendered using
MicroCT, to allow the viewing of the bone formation after 4 and 8 weeks. Figure 3.6.2 shows at
week 4, minimal bridging and bone formation occurred at week 4 in the BMP-2 alone and
combined growth factor groups, while the control bone remained as a non-union, with little to no
healing observed. By week 8, the BMP-2 alone group displayed callus formation and bridging
around the allograft, while the combined group showed an increase of bone healing and a nearly
complete bony union was formed at the defect site.
37

Figure 3.6.1: MicroCT radiographs of control, BMP-2, and combined growth factor groups after
4 and 8 weeks of allograft implantation. No callus formation or bridging was seen in the control
group. Callused bridging was seen in week 8 in the BMP-2 group, and at both week 4 and 8 for
the combined group.

Figure 3.6.2: 3D rendered images of the defect/healing site. Control groups showed very little
bone formation. A partial bony union was observed by 8 weeks in the BMP-2 alone group, while
increased bone bridging was seen by 8 weeks in the BMP-2 and VEGF group, with partial
bridging seen at week 4 for the same group.
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4 Discussion
4.1. Polymer Degradation
The polymer coating is the most significant aspect of the delivery of bioactive agents
from coated allografts, as the polymer coating is the means behind growth factor and antibiotic
loading, as well as the driving force for delivery due to degradation. Preliminary studies of this
project characterized the most efficient procedure for coating allografts with PLGA. Using
MicroCT to quantify the coating volume, and SEM imaging to qualify the extent of the coating,
it was determined that a polymer concentration of 1:14 was the most ideal in terms of the coating
extent and porosity. The polymer solution was viscous enough that it covered the entire allograft
and infiltrated the porous matrix of the bone. Concentrations of 1:12 were too viscous, and
clogged some of the allograft pores, effectively eliminating the natural porous nature of the bone,
while polymer concentrations of 1:20 produced a minimal coating volume that left small regions
of uncoated bone.
SEM images were taken to assess and characterize the PLGA degradation from being
submerged in PBS for up to 42 days, in order to establish a proper time period for encapsulated
in vitro release studies to take place. PLGA degradation is the mechanism behind drug delivery
in this case, and the SEM images were used to verify that the polymer degradation was occurring
in a pattern that correlated to the in vitro release. Bones submerged in PBS for 3 days showed a
fully coated allograft with very little uncoated bone, however the majority of growth factor is
released during this first day. This can be explained because the burst release is not due to
hydrolytic degradation of PLGA, but rather the interaction of PBS and the proteins bound to the
surface of the polymer coated allograft, as well as their solubility. SEM images were taken for
bones submerged for 3, 5, and 7 days, and every week after that for 6 weeks. Each successive
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time point showed a slightly larger region of uncoated bone, represented by a lighter, jagged
appearance, indicating that the polymer had begun to degrade. This slow process of degradation
represents the gradual release of encapsulated BMP-2 and gentamicin after the initial burst,
corresponding the polymer degradation to the drug release. However despite gradually
degrading, a PLGA coating was still present on the allograft, indicating the graft’s ability to
encapsulate and release proteins in a sustained and long term manner. By time points even as late
as 4 weeks, PLGA coated still was visible on the allograft, however by the time the allograft
submerged for 42 days was imaged, it was noted that it was nearly all uncoated bone, suggesting
nearly complete polymer degradation. This serves as a suggestion and verification of how long in
vitro release studies should occur, based on the premise that the therapeutic agents will have
been completely released by the time the PLGA has degraded. This study did not research the
possibility of growth factors or antibiotics binding to the graft itself, and the qualitative results of
this study were analyzed under the principle that the therapeutic agents will be completely
released when there is no polymer left. Because no PLGA was seen by week 6, it is an indication
that there is no more growth factors or antibiotics bound to the system yet to be delivered, thus a
6 week time point is sufficient to gather release data. This is additionally seen in the
corresponding plateaus by 6 weeks, and limited release after 4 weeks in the BMP-2 and
gentamicin encapsulation studies.
It is important to note that the polymer degradation study was performed using cortical
allografts and a 1:8 polymer coating, while the in vitro studies were using cancellous allografts,
and most were focused on lower PLGA concentrations. While the pattern of gradual polymer
degradation does correlate to the release profiles observed, there are significant differences that
exist between the two studies. One of the major differences in the lack of pores present in

40

cortical allografts. The presence of pores could introduce variability in the degradation and
coating process, and may have altered how the PLGA degrades compared to the cortical
allografts. The other main difference was the use of a 1:8 PLGA concentration, which was only
used for one in vitro release study in this present work. The preliminary studies determined that
even a 1:12 polymer concentration clogged the native pores of the allograft, and the lower
concentrations of PLGA that were used in the in vitro studies resulted in a lower coating volume,
and potentially a difference in degradation time. Despite the differences in the SEM study and
the in vitro studies, the release kinetics appear to show correlating patterns as seen in the SEM
characterization, and thus the polymer degradation is thought to be similar between the two.
4.2. Release of Encapsulated of BMP-2
BMP-2 encapsulation followed the trend established from the SEM characterization
study. An initial burst release of 82%, 67%, and 53% for 1:8, 1:14 and 1:20 was observed, and is
likely caused by the contact between the PBS and surface of the polymer coating. The burst
release for the 1:8 PLGA concentration is significantly larger than the other two concentrations,
however it’s possible that since time points have only been taken up to day 28, there is still
potential BMP-2 to be released, which would result in a smaller burst release relative to the
cumulative concentration. However, at the 28 day time point, 97% and 96% of BMP-2 was
released from the 1:14 and 1:20 PLGA. If a similar trend is followed in the remaining 2 weeks of
release from the 1:8 concentration, there will not be significant increases in the cumulative
release. After burst release, sustained release was achieved up until around 21 days and
eventually stopped releasing by day 42, again following the trend of the polymer slowly bulk
degrading during this time period. The plateau seen by the end of the study indicates no further
release is occurring, a trend that is related to very little polymer coating left on the allograft as
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seen in the SEM degradation study images. Encapsulating BMP-2 within the polymer matrix will
provide protection from the physiological environment, and prolong its very short half-life [19].
This, in combination with the prolonged release, will allow BMP-2 to remain at the defect site
for up to 6 weeks, an occurrence that is typically achieved by frequent or supraphysiological
dosage amounts [31]. The continuous, prolonged presence of BMP-2 will continue to stimulate
osteoprogenitor cells, such as hMSCs, to proliferate and differentiate into bone forming
osteoblast cells, a process that mimics the natural bone healing process. Preliminary studies
assessed the burst release of VEGF, attempting to mimic natural bone healing as initial release of
VEGF begins vessel formation. This study targets the natural healing process by continuously
delivering BMP-2, which is naturally found at the defect site for a longer period of time,
observed by bone callus formation occurring for 4 to 6 weeks after injury. By achieving a slight
release, BMP-2 can be introduced in the system and immediately begin to differentiate bone
forming cells, but the true significance lies in the ability for the allograft to maintain the delivery
of BMP-2, biomimetically stimulating new bone growth for a duration of 6 weeks. This is
hypothesized to result in an allograft that has enhanced osteoinductive properties and bone
formation, due to the extended delivery of osteogenic growth factors, as well as an initial burst
release to begin the process of new bone formation upon implantation.
It is also significant to observe that the cumulative release of BMP-2 was larger with
higher PLGA coating concentrations. This correlates to the preliminary studies, demonstrating
that higher concentrations had a higher coating volume. The 1:20 concentration insufficiently
infiltrated the entire porous nature of allograft, and led to a decreased coating volume. With a
decrease in coating volume, the 1:20 PLGA concentration was unable to attach and bind to as
much of the protein as the higher concentrations. The 1:14 concentration showed extended and
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continuous coating throughout the allograft, and the 1:8 concentration was not imaged, though
MicroCT verified it had the highest coating volume of all 3 polymer concentrations. This results
in larger coating volumes having a larger surface area to bind proteins. These results were
verified by quantification, showing that 1:14 PLGA released 92 ng/ml, almost three times as
much as the 33 ng/ml released by the 1:20 PLGA concentration. By day 28 the BMP-2 released
from 1:8 PLGA already had a cumulative release concentration of 130 ng/ml. Additionally, the
results provide evidence to the hypothesis that varying polymer concentration will subsequently
vary the release kinetics, and demonstrate the flexibility the coated allografts can achieve by
modifying both polymer and factor loading concentrations. The significance of a flexible,
variable allograft is beneficial for clinical applications. Depending on the type, size, and location
of the bone defect site, different polymer concentrations can be synthesized depending on the
amount of growth factor delivery required, while not requiring larger systemic deliveries.
4.3. Release of Encapsulated Gentamicin
The release of encapsulated gentamicin from 1:14 PLGA follows similar trends to that of
encapsulated BMP-2, a burst release following by prolonged delivery. The burst effect of
gentamicin was 63% of the total release, compared to 67% of the total burst release from
encapsulated BMP-2, demonstrating comparable burst release kinetics. The burst release of
gentamicin occurred slightly quicker, with the burst release seen in the first 12 hours compared
to the first day, but this may have potentially been caused by gentamicin’s lower molecular
weight or higher solubility compared to BMP-2. The similar release kinetics serve as verification
that loading and releasing antibiotics can be accomplished in a similar manner to growth factors,
allowing the potential use of the allograft to release a combination of growth factors and
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antibiotics, to fight off bone infection that may arise from the implantation, as well as promote
new bone growth to the defect site.
Following the burst release, gentamicin continued to release from the allografts up until
day 28, and following that began to plateau. This is imperative to the function of antibiotic to
fight bone infection. Antibiotic treatment should continue for 6 weeks post-surgery to properly
prevent osteomyelitis from forming [21]. The slight burst release of gentamicin allows the
antibiotic to be present in physiological amounts locally within a day of allograft implantation,
for immediately defense against infection, and not allow an infection to form to the point where
it becomes difficult to treat. The subsequent sustained release is critical in maintaining antibiotic
presence at the implantation site, to enable the gentamicin to continue to fight off infection for
the recommended six weeks, and ensures that not all gentamicin is released prior to an infection
being fully eliminated. The release kinetics observed in this study are an attempt to mimic
antibiotic treatment of administration in the operating room or even prior to surgery occurring, as
well as for up to 4 to 6 weeks post-surgery. The burst release followed by 28 days of prolonged
release demonstrated in this study suggests the potential the allografts have to release gentamicin
in accordance with standard systemic administration, while being delivered locally to potentially
reduce side effects.
4.4. Release of Surface Adsorbed Gentamicin
Surface adsorbed gentamicin followed a different trend than that of the encapsulated data.
While encapsulated gentamicin had a burst release followed by a sustained release, surface
adsorbed gentamicin showed a much larger burst release, followed by an immediate plateau.
However, both polymer concentrations for this release study showed an additional time point of
release in the middle of the study. This additional release caused the burst release to be less
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pronounced relative to the whole cumulative release of gentamicin. Similar to the encapsulated
BMP-2, the trend of a higher PLGA concentration resulting in more release is also seen in this
case. This aspect is again important in terms of the controllability of the construct. By simply
altering the polymer concentration prior to coating, more or less gentamicin can be theoretically
loaded and released from the allograft. In terms of a clinical application, controllability is a
beneficial, and allows the potential of altering the coating parameters based on surgeon or
medical staff advice, for a more patient customized allograft based on their specific defect site.
It is also worth noting that the surface adsorption does not follow the trend of prolonged
release as seen in the encapsulation studies as well as SEM characterization. This trend is
reflected in figure 3.4.2. Surface adsorption delivers a much larger amount of gentamicin within
the first week than encapsulation, however it shows no long term release compared to the
sustainability of encapsulated release. This is due to the mechanism of release of surface
adsorption is not tied to bulk degradation of PLGA, but rather surface diffusion of the proteins
upon placed in PBS, which happens rapidly. Upon the diffusion of the entirety of antibiotic, the
PLGA will continue to degrade. However, no antibiotic was encapsulated within the PLGA
matrix but rather just on the surface, thus the PLGA will degrade but release no further amounts
of antibiotic. The goal of surface adsorption of gentamicin is to use the short term, extreme burst
release in combination with a long term delivery of additional therapeutic agents. An allograft
with surface adsorbed gentamicin would allow a substantial amount of antibiotic to immediately
begin fighting and preventing infection, more so than encapsulated gentamicin. Using biphasic
drug loading and release, this would be combined with encapsulated growth factors or additional
antibiotics, to allow for long term delivery of antibiotics or osteogenic agents, while significantly
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administering a dose of antibiotics immediately following implantation, when the wound site is
most exposed to the environment that will cause infection.
It is worth noting that the gentamicin release studies all showed large standard deviation
errors, as well as large cumulative releases compared to their loading concentrations. In addition,
the surface adsorbed kinetics displayed the irregular increase midway through their release
period. It is thought that the chemical assay synthesized, based on [39] played a role in how the
absorbance values were subsequently calculated into concentration readings. It is thought that the
o-phthalaldehyde in particular is a sensitive chemical, and may be affected by air oxidation,
light, or time since use [40], all factors that could have potentially altered gentamicin readings.
One piece of evidence behind this thought is that based on table 4.3.1 below. This table shows
the absorbance of PBS, the assay, and propanol with no gentamicin loaded, from multiple
standard curves ran throughout the year. In theory, since the 0 μg/ml concentration of the
standard curves are identical solutions, the values would be similar during each run. However, as
the table shows, these values varied greatly between multiple standard curves developed using
identical protocols. This trend is additionally seen in figure 4.3.1 as well. This figure shows all
the standard curves, which in theory should follow the same trend, however the graphs are
shifted up along the Y axis based on what value the PBS and reagent alone had. When standard
curves were corrected by subtracting the 0 μg/ml concentration reading from all values, the
resulting standard curves showed more consistency in terms of slope as well as absorbance
values. This led us to believe that the release profiles for gentamicin are correct in terms of
trends and patterns, but the translation from optical density to a concentration value themselves
might be skewed in the Y axis direction, potentially explaining the large cumulative release, or
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even the bump in surface adsorbed release, as all of the samples of a specific release study were
not quantified on the same day.
Trial

0 μg/ml Absorbance

1

0.979

2

0.276

3

0.649

5

0.953

6

0.293

Standard
Deviation

0.341092363

Table 4.3.1: Variability in absorbance readings for PBS and the assay kit alone
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Figure 4.3.1: The varying gentamicin standard curve ran multiple times throughout the year. The
variability of the standard curves is shown with the shifts up the Y axis.
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Figure 4.3.2: Corrected gentamicin standard curves appear to be more consistent and show
similar trend lines.
4.4 In Vivo Healing of a Critical Size Defect
The aim of the in vivo study was to demonstrate that the combined delivery of BMP-2
and VEGF would ultimately lead to an increased amount of new bone formation in the defect site
after 8 weeks. This hypothesis is based on related literature that dictates a combined delivery of
BMP-2 and VEGF leads to more bone formation than either of the growth factors alone [26-28].
For instance, the sequential release of both VEGF and BMP-2 from poly(propylene fumarate)
scaffolds with gelatin microparticles was shown to accelerate the healing process in a critical size
defect in a rat model [26]. Collagen type I and osteopontin expressions were all found to be
enhanced from the combined delivery of VEGF and BMP-2, indicating increased chemotactic
migration and bone remodeling activity respectively. These results are thought to be due to
VEGF and BMP-2 respective roles of angiogenesis and osteogenesis in bone healing. VEGF is a
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widely used growth factor responsible for the formation of new blood vessels, a key step in bone
or any wound healing process. BMP-2 stimulates osteogenesis due to the proliferation and
differentiation of osteoprogenitor cells into osteoblasts, which form woven bone, and the two
have displayed synergistic effects when delivered together.
The design of the allograft involved encapsulated BMP-2, and surface adsorbed VEGF.
Based on the preliminary studies, the release kinetics should display a burst release of VEGF,
followed by a sustained release of BMP-2 [29]. The proposed design was sought to have an
immediate burst release of VEGF to the defect site to begin the process of angiogenesis. The
accelerated formation of new blood vessels may potentially enhance the formation of new bone,
due to the immediate access of nutrients, cells, oxygen, and waste removal of the defect site. In
addition to angiogenesis, VEGF in combination with the RANK ligand stimulates the process of
osteoclastogenesis [16]. This process breaks down bone to remodel, allowing osteoblasts too lay
down the formation of new bone. This process is targeted in this study from the prolonged
release of the encapsulated BMP-2. BMP-2 stimulates osteoblast differentiation, to form new
bone out of the resorbed mineral substance from osteoclastogenesis. A prolonged release of
BMP-2 could potentially continue to recruit and differentiate osteoblast progenitor cells to
continue to form new bone for a longer period of time.
The radiograph and MicroCT results suggest overall that the combination of growth
factors led to more new bone formation than the control allograft and just BMP-2 alone. A
significant amount of bone formation occurred after 4 weeks in both the experimental groups
compared to the control group, indicating the delivery and viability of the growth factors was
successful. At 4 weeks, more bone was seen in the combined group than the BMP-2 alone group,
as evident from the increased bone bridging and callus formation seen on the radiograph and 3D
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rendered images. This potentially suggests that the synergistic effects of the combined growth
factors was more prominent and effective at earlier time points, a trend that has also been
observed in additional literature [26, 28, 30]. The seemingly accelerated bone healing compared to
just BMP-2 can potentially may be explained by the surface adsorbed burst of VEGF, forming
early blood vessels and resorbing bone for enhanced bone healing. By 8 weeks, the radiographs
and MicroCT showed increases in bone formation between both experimental groups, with
bridging appearing to get closer to approaching complete integration of the graft. The 3D
MicroCT image showed that the control allograft was still unhealed at the defect site, with a
visible gap between the allograft and the host bone. The BMP-2 alone group showed partial
bridging and integration with the host bone by 8 weeks, however there was still partial nonunion. The combined group showed an almost complete bridging and union of the host bone and
allograft. These results indicate that similar to the 4 week time period, the combined synergy of
BMP-2 and VEGF resulting in more bridging and integration with the host bone, and ultimately
enhanced bone healing.
A critical aspect that this study addresses is the use of a controlled and combined delivery
of growth factors to reduce the therapeutic dosage of BMP-2. In additional to large doses of
BMP-2 being expensive, supraphysiological doses can lead to ectopic or cyst-like bone
formation [31, 32]. One of the most popular clinical treatments involved BMP-2, INFUSE bone
graft, contains 1.5 ml/mg rhBMP-2, exceeding the physiological levels of natural BMP-2 [33, 34].
Compared to the 1.5 ml/mg, the allograft used in these study contained 300 ng/ml. Despite
containing orders of magnitude less BMP-2 than 1.5 ml/mg, BMP-2 alone showed enhanced
bone formation compared to control allografts, though not sufficient enough for complete
bridging after only 8 weeks. However, the low dose of BMP-2 combined with VEGF resulted in
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the synergistic effect and almost complete bridging. Additionally, the amount of BMP-2 used in
these allografts were considered sub-optimal therapeutic amounts in rodents [35], however used in
combination with VEGF still achieved the nearly complete bony union. This suggests that the
loading and controlled release of BMP-2, in addition with the combined delivery of BMP-2 and
VEGF, ultimately leads to greater bone formation compared to control allografts, while requiring
magnitudes less growth factor than is currently used clinically.
5 Conclusion
The polymer coating was optimized in the previous study, and this study characterized
and assessed its degradation in vitro, as encapsulated molecules are released through the
degradation process. Preliminary studies, as well our recent BMP-2 release studies performed
show a sustained release up until 6 weeks. This is consistent with the findings of the SEM
degradation, showing qualitatively that polymer coating still remained on the bone throughout
the course of 6 weeks, though less remained at each time point, indicating long term sustained
release of protein. Additionally, at the 6 week time point, very little polymer coating is observed
to remain on the allograft, consistent with the gradual decrease and plateau of cumulative release.
Each release study indicated similar kinetics; surface adsorbed molecules in general showed
significant burst release followed by a very gradual release and plateau, while encapsulated
release showed moderate burst release with prolonged release afterwards. These release kinetics
are important depending on the function of the loaded protein. Long term BMP-2 delivery has
been thought to be beneficial for the continuous differentiation of osteoblasts to form new bone.
Gentamicin would benefit from both immediately release as well as long term delivery, to mimic
the antibiotic protocol used in bone surgery. Lastly, the in vivo implantation of cortical allografts
implanted in a femoral segmental defect indicated that the synergy of angiogenic and osteogenic
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growth factors is more effective than either alone, corroborating with many previous studies. The
combined group showed a more extensive callus formation and bone bridging at both 4 weeks
and 8 weeks. The combined loading resulted in a near bony union after 8 weeks, as well as
enhanced results at 4 weeks compared to BMP-2 alone, potentially indicating the combined
angiogenic and osteogenic growth factor release leads to more accelerated bone healing.
6 Future Directions
There are still many steps, studies, and trials to complete before this bone graft system
would be approved for any clinical applications. We have loaded a variety of therapeutic agents
to allografts, the next likely step will be to show the release kinetics of dually loaded allograft.
This could be performed by encapsulating one protein and surface adsorbing another, such as the
BMP-2 and VEGF combination used in the in vivo studies with positive results. It could also
entail loading the same agent or growth factor both encapsulated and surface adsorbed such as
gentamicin, to achieve significant burst release as well as sustained release for 6 weeks after.
Release kinetics for dually coated allografts need to be measured to ensure dually coated
allografts results in similar trends of burst release of the surface adsorbed protein, and prolonged
release of the encapsulated one, as seen with a single loaded protein. Additional in vitro cell
studies should be performed, such as gentamicin functionality, MTS assays to ensure cell
viability upon protein release, TRAP assay to test osteoclast differentiation, or assays to test
mineralization follow BMP-2 release. The final step to perform will be a similar in vivo study on
an animal model to test new bone formation upon implantation with various growth factors or
gentamicin loaded onto the allograft.
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